Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Nature Immunology|March 25, 2026
MHC class I on target cells regulates CD4+ T cell-mediated immunityEmma Lauder, Mahnoor Gondal, Meng-Chih Wu, et al.Proceedings of the National Academy of Sciences of the United States of America|November 27, 2023
Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapyYi Bao, Yuanyuan Qiao, Jae Eun Choi, et al.Biorxiv : the Preprint Server for Biology|July 30, 2026
Genomic Determinants of Lethality and Therapeutic Vulnerability in Castration-Resistant Prostate CancerRyan J Rebernick, Liat Hammer, Mahnoor Gondal, et al.Science (New York, N.Y.)|June 26, 2025
Divergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticitySanjana Eyunni, Rahul Mannan, Yuping Zhang, et al.Cancer Discovery|November 14, 2024
The UBA1-STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint BlockadeYi Bao, Gabriel Cruz, Yuping Zhang, et al.Nature Communications|June 28, 2024
PIKfyve, expressed by CD11c-positive cells, controls tumor immunityJae Eun Choi, Yuanyuan Qiao, Ilona Kryczek, et al.Biorxiv : the Preprint Server for Biology|March 11, 2024
PIKfyve controls dendritic cell function and tumor immunityJae Eun Choi, Yuanyuan Qiao, Ilona Kryczek, et al.The Journal of Clinical Investigation|September 16, 2025
CDK12/13 inactivation triggers STING-mediated antitumor immunity in preclinical modelsYi Bao, Yu Chang, Jean Ching-Yi Tien, et al.Pageof 1